Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from GSK

The impact Trump’s tariffs could have on the NHS

IN FULL

The Independent UK

Pharmaceuticals are the next Trump tariff battleground - what will they mean for the NHS?

TRUMP TARIFFS: UK-based drug companies AstraZeneca and GSK could be affected by Trump’s next decision, as Karl Matchett reports

The Independent UK

EU drug companies warn of exodus to US as Trump threatens import tariffs

Von der Leyen urged to take ‘rapid and radical action’ as president says tariffs on pharmaceuticals coming ‘shortly’

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump tariffs: Which UK sectors will be hit hardest?

The PA news agency looks at which sectors will be most affected by the plans and what it means for businesses and households.

Evening Standard

Shingles vaccine tied to a 20% lower risk of dementia among older people

The findings add to a growing body of evidence that the shingles vaccine may help keep dementia at bay – but researchers still need to prove it.

Euronews

GSK employees perform anonymous ‘180’ surveys on their bosses, and CEO Emma Walmsley isn’t exempt

Emma Walmsley says her "180" would probably tell her to say "thank yous" and "well dones."

Fortune

FDA approves new UTI antibiotic that may help patients with recurring infections

A commercial launch of the antibiotic in the U.S. is planned during the second half of 2025

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

New Antibiotics For UTI Gets FDA Approval- First In 30 Years

The FDA has approved a new antibiotic, Gepotidacin (Blujepa), for treating uncomplicated urinary tract infections (UTIs) in women and girls aged 12 and older.

Medical Daily

From $6 billion unicorn to bankrupt cautionary tale: The story of 23andMe

DNA testing company 23andMe was a white-hot Silicon Valley startup for years, and Anne Wojcicki was a celebrity CEO. But after going public, investors lost faith in the DNA testing company.

Fortune

Pfizer offloads final shares in Sensodyne maker Haleon

Haleon was formed in 2019 by the merger of the consumer healthcare businesses of British pharmaceutical group GSK and US rival Pfizer.

Evening Standard

Doctors didn’t warn ‘deviant sexual behaviour’ was side effect of restless legs syndrome drug

Patients claim GPs did not tell them about significant potential side effects of treatment

The Independent UK

Power Players: Meet the women reshaping 10 key European industries

This year, Fortune curated a list of female leaders at the helm of European companies across the continent’s biggest industries.

Fortune

23andMe was once worth $6 billion. Now CEO Anne Wojcicki wants to buy it back for $42 million

Experts say the CEO’s second attempt to buy back the troubled DNA startup comes with a slew of corporate governance red flags.

Fortune

British pharma company GSK pauses diversity work citing Trump orders

London-based FTSE 100 firm reviewing its policies, saying it is obliged to comply because US is its No 1 market

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

GSK could double CEO Emma Walmsley's pay to $27 million

The British pharma giant said Emma Walmsley's current pay could put off candidates for her eventual successor.

The Guardian - UK

GSK boss Emma Walmsley’s pay could rise to nearly £22m in three years’ time

UK pharmaceutical companies aim to put executive pay on par with US rivals’ but package will depend on share price

The Guardian - UK

Women hold almost 45% of seats on FTSE 100 boards, report says

New high tempered by dip in number of female CEOs at 100 biggest listed firms to fewer than 10 last year

The Guardian - UK

AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?

When the pharma firm cancelled plans for a major expansion of its Merseyside plant last month, there was no shortage of questions – or blame – over responsibility

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

Despite Profit Fallout, GSK Remains Optimist For 2031 Revenue Target Amidst Cancer Drug Sale Rise

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

The Guardian - UK

Drug firm GSK delivers a syringe full of crowd-pleasers

Pharmaceuticals company’s higher dividend, upgrade to revenues and share buyback suggest its drugs pipeline is flowing nicely

The Guardian - UK

Novo Nordisk confident despite Trump tariff risk as sales of weight-loss jab soar

Europe’s biggest firm, whose sales of Wegovy almost doubled, feels it can ‘meet demands’ of US administration

Evening Standard

GSK lifts long-term sales targets on new drug pipeline

It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024.

The Guardian - UK

The ‘super powerful’ tool behind a pharmaceutical giant’s global regulatory operation

When GSK’s regulatory teams needed help to sharpen up their project management, they turned to Smartsheet to reduce admin, increase collaboration and enhance performance overall

The Independent UK

Cancer vaccine being created by UK scientists could stop disease up to 20 years early

A new partnership between the University of Oxford and GSK aims to develop vaccines against cancer before develop

The Independent UK

New cancer vaccine to stop disease before it takes hold in the body

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine

1 … 5 6 7 8

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.